{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:53:46Z","timestamp":1791975226521,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alanya Alaaddin Keykubat University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The incidence of breast cancer has been increasing in recent years, and monotherapy approaches are not sufficient alone in the treatment of breast cancer. In the combined therapy approach, combining two or three different agents in lower doses can mitigate the side effects on living cells and tissues caused by high doses of chemical agents used alone. ABT-263 (navitoclax), a clinically tested Bcl-2 family protein inhibitor, has shown limited success in clinical trials due to the development of resistance to monotherapy in breast cancer cells. This resistance shows that monotherapy approaches are inadequate and more effective treatment strategies are needed. It is the ability of HSP90 inhibitors to destabilize many oncoproteins that are critical for the survival of cancer cells. This study aimed to examine the anticancer activity of the combination of ABT-263 with BIIB021, a new generation HSP90 inhibitor, on two widely used breast cancer cell lines: MCF-7 (ER-positive) and MDA-MB-231 (triple-negative breast cancer, TNBC). These cell lines were selected to represent distinct breast cancer subtypes with different molecular characteristics and clinical behaviors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p> Single and combined cytotoxic effects of this agents on MCF-7 and MDA-MB-231 breast cancer cell lines were determined using the MTT cell viability test. The combined use of these two agents showed a synergistic effect, and this effect was assigned using the Chou and Talalay method. mRNA and protein levels of apoptosis-related genes Bax, Bcl-2, Casp9, and Heat Shock Proteins HSP27, HSP70, and HSP90 were analyzed using Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western Blotting, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The cytotoxicity analysis, combined with the application of the Chou-Talalay method, demonstrated that the BIIB021 and ABT-263 combination exhibited significantly greater anticancer activity compared to the individual effects of either BIIB021 or ABT-263 in breast cancer cell lines. The analysis of mRNA and protein levels indicated that the BIIB021+ABT-263 combination may have triggered the intrinsic apoptotic pathway in breast cancer cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>   This study showed that\u00a0co-administration of ABT-263 and BIIB021 agents exhibited synergistic cytotoxic effects and increased the expression of apoptosis-related genes in breast cancer cell lines <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s10549-024-07587-1","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T03:57:35Z","timestamp":1736395055000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263"],"prefix":"10.1007","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-1067","authenticated-orcid":false,"given":"Nazan","family":"G\u00f6k\u015fen Tosun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-4556","authenticated-orcid":false,"given":"\u00d6zlem","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"7587_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174287","journal-title":"Cancers (Basel)"},{"key":"7587_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","volume":"10","author":"JDB Fuentes","year":"2024","unstructured":"Fuentes JDB, Morgan E, de Luna AA, Mafra A, Shah R, Giusti F et al (2024) Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol 10:71\u201378","journal-title":"JAMA Oncol"},{"key":"7587_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast 66:15\u201323","journal-title":"The Breast"},{"key":"7587_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02807-9","author":"N G\u00f6k\u015fen Tosun","year":"2023","unstructured":"G\u00f6k\u015fen Tosun N (2023) Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-023-02807-9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"7587_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/bctt.S432526","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang J, Wu SG (2023) Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer (Dove Med Press) 15:721\u2013730. https:\/\/doi.org\/10.2147\/bctt.S432526","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"7587_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/pharmaceutics12121193","volume":"12","author":"PdF Lainetti","year":"2020","unstructured":"Lainetti PdF, Leis-Filho AF, Laufer-Amorim R, Battazza A, Fonseca-Alves CE (2020) Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics 12:1193","journal-title":"Pharmaceutics"},{"key":"7587_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","volume":"10","author":"J Chen","year":"2011","unstructured":"Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ et al (2011) The Bcl-2\/Bcl-XL\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10:2340\u20132349","journal-title":"Mol Cancer Ther"},{"key":"7587_CR8","doi-asserted-by":"crossref","unstructured":"Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A (2020) Clinical review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. Front Pharmacol 11:564108","DOI":"10.3389\/fphar.2020.564108"},{"key":"7587_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/pharmaceutics13091353","volume":"13","author":"NS Nor Hisam","year":"2021","unstructured":"Nor Hisam NS, Ugusman A, Rajab NF, Ahmad MF, Fenech M, Liew SL et al (2021) Combination therapy of navitoclax with chemotherapeutic agents in solid tumors and blood cancer: a review of current evidence. Pharmaceutics 13:1353","journal-title":"Pharmaceutics"},{"key":"7587_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10637-014-0110-9","volume":"32","author":"JM Cleary","year":"2014","unstructured":"Cleary JM, Lima CMSR, Hurwitz HI, Montero AJ, Franklin C, Yang J et al (2014) A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs 32:937\u2013945","journal-title":"Invest New Drugs"},{"key":"7587_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, De Oliveira MR, Bonomi P, Gandara D, Khaira D et al (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29:909","journal-title":"J Clin Oncol"},{"key":"7587_CR12","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS et al (2015) A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 56:2826\u20132833","journal-title":"Leuk Lymphoma"},{"key":"7587_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tiv.2017.09.023","volume":"46","author":"EY Lee","year":"2018","unstructured":"Lee EY, Gong EY, Shin JS, Moon JH, Shim HJ, Kim SM et al (2018) Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. Toxicol In Vitro 46:229\u2013236. https:\/\/doi.org\/10.1016\/j.tiv.2017.09.023","journal-title":"Toxicol In Vitro"},{"key":"7587_CR14","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B et al (2017) Combination therapy in combating cancer. Oncotarget 8:38022\u201338043. https:\/\/doi.org\/10.18632\/oncotarget.16723","journal-title":"Oncotarget"},{"key":"7587_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12032-023-02181-9","volume":"40","author":"\u00d6 Kaplan","year":"2023","unstructured":"Kaplan \u00d6 (2023) Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888. Med Oncol 40:318. https:\/\/doi.org\/10.1007\/s12032-023-02181-9","journal-title":"Med Oncol"},{"key":"7587_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.470","volume":"5","author":"H Wei","year":"2020","unstructured":"Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A et al (2020) (2024) Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm 5:e470. https:\/\/doi.org\/10.1002\/mco2.470","journal-title":"MedComm"},{"key":"7587_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J (2017) The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 18:345\u2013360","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7587_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2015.02.026","volume":"360","author":"GD Lianos","year":"2015","unstructured":"Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L et al (2015) The role of heat shock proteins in cancer. Cancer Lett 360:114\u2013118","journal-title":"Cancer Lett"},{"key":"7587_CR19","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8443","author":"ZN Li","year":"2023","unstructured":"Li ZN, Luo Y (2023) HSP90 inhibitors and cancer: Prospects for use in targeted therapies (review). Oncol Rep. https:\/\/doi.org\/10.3892\/or.2022.8443","journal-title":"Oncol Rep"},{"key":"7587_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12094-010-0486-8","volume":"12","author":"A Gim\u00e9nez Ortiz","year":"2010","unstructured":"Gim\u00e9nez Ortiz A, Montalar Salcedo J (2010) Heat shock proteins as targets in oncology. Clin Transl Oncol 12:166\u2013173","journal-title":"Clin Transl Oncol"},{"key":"7587_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2017.09.040","volume":"411","author":"H Yang","year":"2017","unstructured":"Yang H, Lee M-H, Park I, Jeon H, Choi J, Seo S et al (2017) HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Lett 411:19\u201326. https:\/\/doi.org\/10.1016\/j.canlet.2017.09.040","journal-title":"Cancer Lett"},{"key":"7587_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/1568009619666191202101330","volume":"20","author":"J Sanchez","year":"2020","unstructured":"Sanchez J, Carter TR, Cohen MS, Blagg BSJ (2020) Old and new approaches to target the Hsp90 chaperone. Curr Cancer Drug Targets 20:253\u2013270. https:\/\/doi.org\/10.2174\/1568009619666191202101330","journal-title":"Curr Cancer Drug Targets"},{"key":"7587_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/15748928113089990031","volume":"9","author":"K Sidera","year":"2014","unstructured":"Sidera K, Patsavoudi E (2014) HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anti-Cancer Drug Discov 9:1\u201320","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"key":"7587_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112063","volume":"189","author":"TE Costa","year":"2020","unstructured":"Costa TE, Raghavendra NM, Penido C (2020) Natural heat shock protein 90 inhibitors in cancer and inflammation. Eur J Med Chem 189:112063","journal-title":"Eur J Med Chem"},{"key":"7587_CR25","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3390\/cells11162556","volume":"11","author":"X Ren","year":"2022","unstructured":"Ren X, Li T, Zhang W, Yang X (2022) Targeting heat-shock protein 90 in cancer: an update on combination therapy. Cells 11:2556","journal-title":"Cells"},{"key":"7587_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64\u201376","journal-title":"Clin Cancer Res"},{"key":"7587_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.tibs.2014.12.002","volume":"40","author":"GE Karag\u00f6z","year":"2015","unstructured":"Karag\u00f6z GE, R\u00fcdiger SG (2015) Hsp90 interaction with clients. Trends Biochem Sci 40:117\u2013125","journal-title":"Trends Biochem Sci"},{"key":"7587_CR28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","volume":"63","author":"L Li","year":"2019","unstructured":"Li L, Wang L, You Q-D, Xu X-L (2019) Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions. J Med Chem 63:1798\u20131822","journal-title":"J Med Chem"},{"key":"7587_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/annonc\/mds275","volume":"24","author":"M Dickson","year":"2013","unstructured":"Dickson M, Okuno S, Keohan M, Maki R, D\u2019adamo D, Akhurst T et al (2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 24:252\u2013257","journal-title":"Ann Oncol"},{"key":"7587_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1535-7163.Mct-08-0758","volume":"8","author":"K Lundgren","year":"2009","unstructured":"Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 8:921\u2013929. https:\/\/doi.org\/10.1158\/1535-7163.Mct-08-0758","journal-title":"Mol Cancer Ther"},{"key":"7587_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1158\/1078-0432.CCR-13-1257","volume":"20","author":"MW Saif","year":"2014","unstructured":"Saif MW, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J et al (2014) A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin Cancer Res 20:445\u2013455. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1257","journal-title":"Clin Cancer Res"},{"key":"7587_CR32","first-page":"3","volume":"40","author":"W He","year":"2018","unstructured":"He W, Hu H (2018) BIIB021, an Hsp90 inhibitor: a promising therapeutic strategy for blood malignancies. Oncol Rep 40:3\u201315","journal-title":"Oncol Rep"},{"key":"7587_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135959","volume":"1291","author":"N G\u00f6k\u015fen Tosun","year":"2023","unstructured":"G\u00f6k\u015fen Tosun N, Erden Tayhan S, G\u00f6k\u00e7e \u0130, Alkan C (2023) Doxorubicin-loaded mPEG-pPAd-mPEG triblock polymeric nanoparticles for drug delivery systems: preparation and in vitro evaluation. J Mol Struct 1291:135959. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135959","journal-title":"J Mol Struct"},{"key":"7587_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105565","volume":"95","author":"\u00d6 Kaplan","year":"2024","unstructured":"Kaplan \u00d6, G\u00f6k MK, Pekmez M, Erden Tayhan S, \u00d6zg\u00fcm\u00fc\u015f S, G\u00f6k\u00e7e \u0130 et al (2024) Development of recombinant protein-based nanoparticle systems for inducing tumor cell apoptosis: In vitro evaluation of their cytotoxic and apoptotic effects on cancer cells. J Drug Deliv Sci Technol 95:105565. https:\/\/doi.org\/10.1016\/j.jddst.2024.105565","journal-title":"J Drug Deliv Sci Technol"},{"key":"7587_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.synres.2018.04.001","volume":"7","author":"T-C Chou","year":"2018","unstructured":"Chou T-C (2018) The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy 7:49\u201350. https:\/\/doi.org\/10.1016\/j.synres.2018.04.001","journal-title":"Synergy"},{"key":"7587_CR36","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1073\/pnas.1104778108","volume":"109","author":"SR Oakes","year":"2012","unstructured":"Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F et al (2012) Sensitization of BCL-2\u2013expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci 109:2766\u20132771","journal-title":"Proc Natl Acad Sci"},{"key":"7587_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","volume":"24","author":"F Vaillant","year":"2013","unstructured":"Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME et al (2013) Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24:120\u2013129","journal-title":"Cancer Cell"},{"key":"7587_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrd1609","volume":"4","author":"CT Keith","year":"2005","unstructured":"Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discovery 4:71\u201378. https:\/\/doi.org\/10.1038\/nrd1609","journal-title":"Nat Rev Drug Discovery"},{"key":"7587_CR39","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1039\/c0ib00130a","volume":"3","author":"TC Chou","year":"2011","unstructured":"Chou TC (2011) The mass-action law based algorithms for quantitative econo-green bio-research. Integr Biol (Camb) 3:548\u2013559. https:\/\/doi.org\/10.1039\/c0ib00130a","journal-title":"Integr Biol (Camb)"},{"key":"7587_CR40","first-page":"97","volume":"6","author":"N Zhang","year":"2016","unstructured":"Zhang N, Fu JN, Chou TC (2016) Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res 6:97\u2013104","journal-title":"Am J Cancer Res"},{"key":"7587_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173919","volume":"897","author":"V Banerjee","year":"2021","unstructured":"Banerjee V, Sharda N, Huse J, Singh D, Sokolov D, Czinn SJ et al (2021) Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: using the Chou-Talalay combination index method. Eur J Pharmacol 897:173919. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173919","journal-title":"Eur J Pharmacol"},{"key":"7587_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12032-023-02107-5","volume":"40","author":"D Karademir","year":"2023","unstructured":"Karademir D, \u00d6zg\u00fcr A (2023) The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells. Med Oncol 40:234. https:\/\/doi.org\/10.1007\/s12032-023-02107-5","journal-title":"Med Oncol"},{"key":"7587_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020230","author":"G Subaiea","year":"2023","unstructured":"Subaiea G, Rizvi SMD, Yadav HKS, Al Hagbani T, Abdallah MH, Khafagy ES et al (2023) Ganetespib with methotrexate acts synergistically to impede NF-\u03baB\/p65 signaling in human lung cancer A549 cells. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16020230","journal-title":"Pharmaceuticals (Basel)"},{"key":"7587_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537\u2013549. https:\/\/doi.org\/10.1038\/nrc2887","journal-title":"Nat Rev Cancer"},{"key":"7587_CR45","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/ijc.31963","volume":"144","author":"G Augello","year":"2019","unstructured":"Augello G, Emma MR, Cusimano A, Azzolina A, Mongiov\u00ec S, Puleio R et al (2019) Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J Cancer 144:2613\u20132624. https:\/\/doi.org\/10.1002\/ijc.31963","journal-title":"Int J Cancer"},{"key":"7587_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495\u2013516. https:\/\/doi.org\/10.1080\/01926230701320337","journal-title":"Toxicol Pathol"},{"key":"7587_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bjh.12215","volume":"161","author":"EJ Walsby","year":"2013","unstructured":"Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK (2013) The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br J Haematol 161:57\u201367. https:\/\/doi.org\/10.1111\/bjh.12215","journal-title":"Br J Haematol"},{"key":"7587_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030587","author":"Z Albakova","year":"2020","unstructured":"Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM (2020) HSP70 multi-functionality in cancer. Cells. https:\/\/doi.org\/10.3390\/cells9030587","journal-title":"Cells"},{"key":"7587_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/35019501","volume":"2","author":"HM Beere","year":"2000","unstructured":"Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T et al (2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2:469\u2013475","journal-title":"Nat Cell Biol"},{"key":"7587_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/cancers11081195","volume":"11","author":"S-K Choi","year":"2019","unstructured":"Choi S-K, Kam H, Kim K-Y, Park SI, Lee Y-S (2019) Targeting heat shock protein 27 in cancer: a druggable target for cancer treatment? Cancers 11:1195","journal-title":"Cancers"},{"key":"7587_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/sj.cdd.4400597","volume":"7","author":"KM Murphy","year":"2000","unstructured":"Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB (2000) Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ 7:102\u2013111. https:\/\/doi.org\/10.1038\/sj.cdd.4400597","journal-title":"Cell Death Differ"},{"key":"7587_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.yexcr.2014.08.039","volume":"328","author":"B Wang","year":"2014","unstructured":"Wang B, Chen L, Ni Z, Dai X, Qin L, Wu Y et al (2014) Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Exp Cell Res 328:379\u2013387. https:\/\/doi.org\/10.1016\/j.yexcr.2014.08.039","journal-title":"Exp Cell Res"},{"key":"7587_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010018","author":"U Testa","year":"2020","unstructured":"Testa U, Castelli G, Pelosi E (2020) Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci (Basel). https:\/\/doi.org\/10.3390\/medsci8010018","journal-title":"Med Sci (Basel)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07587-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:36:26Z","timestamp":1742783786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7587"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07587-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}